"FDA is recommending health care professionals discontinue prescribing and dispensing prescription combination drug products that contain more than 325 milligrams (mg) of acetaminophen per tablet, capsule or other dosage unit. There are no"...
(Generic versions may still be available.)
TONOCARD (tocainide hcl) commonly produces minor, transient, nervous system and gastrointestinal adverse reactions, but is otherwise generally well tolerated. TONOCARD (tocainide hcl) has been evaluated in both short-term (n = 1,358) and long-term (n = 262) controlled studies as well as a compassionate use program. Dosages were lower in most of the controlled studies (1200 mg/day) and higher in the compassionate use program (1800 mg and more). In long-term (2-6 months) controlled studies, the most frequent adverse reactions were dizziness/vertigo (15.3 percent), nausea, (14.5 percent), paresthesia (9.2 percent), and tremor (8.4 percent). These reactions were generally mild, transient, dose-related and reversible with a reduction in dosage, by taking the drug with food, or by therapy discontinuation. Tremor, when present, may be useful as a clinical indicator that the maximum dose is being approached. Adverse reactions leading to therapy discontinuation occurred in 21 percent of patients in long-term controlled trials and were usually related to the nervous system or digestive system.
Adverse reactions occurring in greater than one percent of patients from the short-term and long-term controlled studies appear in the following table:
|Body System / |
| Percent of Patients |
|Short-term (n=1,358)||Long-term (n=262)|
|BODY AS A WHOLE|
|Left ventricular failure||1.4||0.0|
|Diarrhea/ loose stools||0.0||3.8|
|Blurred vision/visual disturbances||1.3||1.5|
An additional group of about 2,000 patients has been treated in a program allowing for the use of TONOCARD (tocainide hcl) under compassionate use circumstances. These patients were seriously ill with the large majority on multiple drug therapy, and comparatively high doses of TONOCARD (tocainide hcl) were used. Fifty-four percent of the patients continued in the program for one year or longer, and 12 percent were treated for longer than three years, with the longest duration of therapy being nine years. Adverse reactions leading to therapy discontinuation occurred in 12 percent of patients (usually central nervous system effects or rash). A tabulation of adverse reactions occurring in one percent or more of patients follows:
|Body System / |
|Percent of Patients Compassionate Use (n=1,927)|
|Increased ventricular arrhythmias/PVCs|| |
|CHF/progression of CHF|| |
|Conduction disorders|| |
|Rash/Skin lesion|| |
|Blurred vision/vision disturbances||10.0|
Adverse reactions occurring in less than one percent of patients, in either the controlled studies on the compassionate use program or since the drug was marketed, are as follows:
Cardiovascular: Ventricular fibrillation; extension of acute myocardial infarction; cardiogenic shock; pulmonary embolism; angina; AV block; hypertension; claudication; increased QRS duration; pleurisy/pericarditis; prolonged QT interval; right bundle branch block; cardiomegaly; sinus arrest; vasculitis; orthostatic hypotension; cold extremities.
Digestive: Hepatitis, jaundice (see PRECAUTlONS), abnormal liver function tests, pancreatitis, abdominal pain and discomfort; constipation; dysphagia; gastrointestinal symptoms (including dyspepsia); stomatitis; dry mouth; thirst.
Nervous System/Psychiatric: Coma; convulsions/seizures; myasthenia gravis; depression; psychosis; psychic disturbances; agitation; decreased mental acuity; dysarthria; impaired memory; increased stuttering/slurred speech; insomnia/sleeping disturbances; local anesthesia; dream abnormalities.
Agranulocytosis, bone marrow depression, leukopenia, neutropenia, aplastic/hypoplastic anemia, and thrombocytopenia have been reported (0.18 percent) in patients receiving TONOCARD (tocainide hcl) in controlled trials and the compassionate use program. Most of these events have been noted during the first 12 weeks of therapy. (See Boxed WARNINGS.)
Pulmonary fibrosis, interstitial pneumonitis, fibrosing alveolitis, pulmonary edema, and pneumonia, have been reported in patients receiving TONOCARD. (tocainide hcl) The incidence of pulmonary fibrosis (including interstitial pneumonitis and fibrosing alveolitis) was 0.11 percent in controlled trials and the compassionate use program. These events usually occurred in seriously ill patients. Symptoms of these pulmonary disorders and/or x-ray changes usually occurred following 3-18 weeks of therapy. Fatalities have been reported. (See Boxed WARNINGS.)
A number of disorders, in which a causal relationship with TONOCARD (tocainide hcl) has not been established, have been reported in seriously ill patients. These include: renal failure; renal dysfunction; myocardial infarction; cerebrovascular accidents and transient ischemic attacks. These disorders may be related to the patient†s underlying condition.
DRUG ABUSE AND DEPENDENCE
Read the Tonocard (tocainide hcl) Side Effects Center for a complete guide to possible side effects
Tocainide and lidocaine are pharmacodynamically similar. The concomitant use of these two agents may cause an increased incidence of adverse reactions, including central nervous system adverse reactions such as seizure.
Specific interaction studies with cimetidine, digoxin, metoprolol and warfarin have been conducted, no clinically significant interaction was seen with cimetidine, digoxin or warfarin; but tocainide and metoprolol had additive effects on wedge pressure and cardiac index. TONOCARD (tocainide hcl) has also been used in open studies with digitalis, beta-blocking agents, other antiarrhythmic agents, anticoagulants, and diuretics, without evidence of clinically significant interactions. Nevertheless, caution should be exercised in the use of multiple drug therapy.
TONOCARD (tocainide hcl) is equally effective in digitalized and non-digitalized patients. In 17 patients with refractory ventricular arrhythmias on concomitant therapy, serum digoxin levels (1.1 ±0.4 ng/mL) remained in the expected normal range (0.5-2.5 ng/mL) during tocainide administration.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Tonocard Information
Report Problems to the Food and Drug Administration
Find out what women really need.